InCarda
Overview
Atrial Fibrillation (AF) is the most common cardiac arrhythmia, affecting over 6 million people with an annual cost of $10.1B in the U.S. alone. Approximately 30-40% of this population have Paroxysmal Atrial Fibrillation (PAF).
The Issue
InCarda therapeutics is developing a novel medication called InRhythm that’s a nebulized formulation of an antiarrhythmic medication called flecainide acetate. This novel medication provides the symptomatic PAF patient the treatment option of self-administering the orally inhaled flecainide, and provides acute cardioversion to sinus rhythm via the lung delivery route. InRhythm can be self-administered by patients on an outpatient basis as needed, compared to the costly current standard of care that involves emergency services and a likely hospital admission.
Approach
The MTM team is developing the infrastructure for InCarda’s treatment paradigm. It includes a stakeholder analysis of the combination of wearable devices, telehealth platforms, reimbursement strategy, and a market analysis.
MTM Student Engagement
The MTM team’s efforts will potentially improve InRhythm’s market entry and user adoption, leading to increased prescriptions and revenue. Patients will be empowered to self-treat their PAF at home, with an optional form of clinical support via telemedicine that includes remote monitoring and wearable devices.